Medindia
☰
Unlock the benefits of registration Click Here
Medindia » Cancer News

Tissue Time Machine Integrated With 3D Maps Of Glioblastomas

by Karishma Abhishek on October 9, 2021 at 11:59 PM

First detailed 3D maps of human glioblastomas predict therapeutic response for a brain tumor with integrated �tissue time machine' as per a study at the Wyss Center for Bio and Neuroengineering.


This will help improve understanding of the brain cancer glioblastoma and help develop therapies that are more effective.

‘First detailed 3D maps of human glioblastomas predict therapeutic response for a brain tumor with the integrated tissue time machine. ’

Glioblastoma (GBM) is the most common and aggressive brain tumor worldwide that is incurable. The recurrence of GBM depends on the tumor microenvironment (TME) , which change over time. This includes tumor cells, immune cells, molecules released by these cells, blood vessels, and hypoxic areas of low oxygen.

3D Maps for Glioblastoma

Thus, by accurately mapping these TME in recurrent tumors before and after treatment, the study team plans to build a model - a �tissue time machine' - that may help predict the therapeutic response.

"We will combine state-of-the-art imaging and computational analysis to reveal the 3D anatomy of brain cancer tumors at a cellular level. Using these novel tools, we will map the distribution of biomarkers and tumor blood vessels to help predict responses to new therapies", says Co-Principal Investigator, Nicolas Renier, Ph.D., Research Group Leader at the Laboratory of Structural Plasticity, Paris Brain Institute.

The team also plans integrate the clinical data from patients to 3D maps that will understand how the disease progresses following the therapy.

"We hope that the unique insights of this �tissue time machine' will mean that we can intervene in brain cancer earlier with a truly personalized approach based on the genetic profiles of individual tumors", says Wyss Center's CEO, Mary Tolikas, Ph.D., MBA.

Source: Medindia

View Non AMP Site | Back to top ↑